Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FCRL5 CAR-T clone 947
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FCRL5 CAR-T clone 947 is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target Fc receptor-like 5 (FCRL5), a cell surface marker highly expressed in multiple myeloma (MM) with restricted expression on normal tissues. Clone 947 was developed using humanized single-chain variable fragment (scFv) sequences obtained from ATX mice (Alloy Therapeutics) and specifically targets the membrane-proximal D9 domain of FCRL5 to enhance the formation of the immunological synapse. The CAR construct incorporates a 4-1BB costimulatory domain and a CD3ζ signaling domain. Preclinical studies have demonstrated that clone 947 exhibits potent cytolytic activity against FCRL5-expressing myeloma cell lines and provides significant survival benefits in mouse xenograft models of aggressive MM. It is currently being positioned as a clinical candidate for the treatment of relapsed or refractory multiple myeloma.
- Other names
- FCRL5 CAR-T (clone 947)FCRL5-targeted CAR-T cell therapy (clone 947)
02
Targets
FCRL5 (Fc receptor-like protein 5)
Beyond the preview
Go deeper on FCRL5 CAR-T clone 947.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FCRL5 CAR-T clone 947.